"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT05027581","Chondrochymal® for Subjects With Knee Osteoarthritis (Knee OA)",,"Recruiting","No Results Available","Osteoarthritis, Knee","Drug: Bone marrow mesenchymal stem cells|Drug: hyaluronic acid","Efficacy-Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) assessment|Efficacy-Visual Analogue Scale (VAS) assessment|Efficacy-SF-36 Quality of Life (QoL) health survey questionnaire|Efficacy-Whole-Organ Magnetic Resonance Imaging Score (WORMS)|Efficacy-knee joint space width (JSW)|Efficacy-synovial fluid|Efficacy-rescue medication|Safety-AE/SAE based on NCI-CTCAE v5.0|Safety-vital signs|Safety-laboratory examination|Safety-physical examination","Taiwan Bio Therapeutics Co., Ltd.|A2 Healthcare Taiwan Corporation","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Chondrochymal-01","September 15, 2021","September 10, 2023","September 10, 2024","August 30, 2021",,"September 24, 2021","Taipei Veterans General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT05027581"
2,"NCT03589287","Allogeneic Bone Marrow MSC Therapy for Knee Osteoarthritis",,"Completed","No Results Available","Knee Osteoarthritis","Biological: Chondrochymal®","Number of participants with adverse events as measure of safety and tolerability|Efficacy - Radiographic evidence|Efficacy - WOMAC assessment|Efficacy - Visual Analogue Scale(VAS) assessment|Efficacy - Lequesne Index assessment|Efficacy - Keen Society Score(KSS) assessment|Efficacy - QOL assessment","Taipei Veterans General Hospital, Taiwan|Virginia Contract Research Organization Co., Ltd.","All","40 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","18","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-11-006C","May 2, 2018","May 3, 2019","April 30, 2020","July 17, 2018",,"August 19, 2021","Taipei Veterans General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03589287"
